Log in

Edge Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.03 (-1.27 %)
(As of 09/29/2020 12:00 AM ET)
Today's Range
Now: $2.33
50-Day Range
MA: $4.11
52-Week Range
Now: $2.33
Volume225,303 shs
Average Volume373,201 shs
Market Capitalization$73.42 million
P/E RatioN/A
Dividend YieldN/A
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
Read More
Edge Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EDGE



Sales & Book Value

Annual SalesN/A
Book Value$0.95 per share


Net Income$-40,860,000.00


Market Cap$73.42 million
Next Earnings DateN/A

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.16.
View Edge Therapeutics' earnings history

Who are some of Edge Therapeutics' key competitors?

What other stocks do shareholders of Edge Therapeutics own?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the following people:
  • Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 54)
  • Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 57)
  • Mr. Andrew Saik, Chief Financial Officer (Age 50)
  • Mr. W. Bradford Middlekauff, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. William Shatynski, Sr. Director of Financial Reporting & Controller

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

What is Edge Therapeutics' stock price today?

One share of EDGE stock can currently be purchased for approximately $2.33.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $73.42 million.

What is Edge Therapeutics' official website?

The official website for Edge Therapeutics is www.edgetherapeutics.com.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.